Pharvaris Stock Gets Higher EPS Forecast from HC Wainwright

Pharvaris N.V. (NASDAQ:PHVS) – Equities researchers at HC Wainwright increased their FY2028 EPS estimates for Pharvaris in a research report issued to clients and investors on Tuesday, October 6th. HC Wainwright analyst P. Trucchio now anticipates that the company will post earnings per share of ($0.48) for the year, up from their prior estimate of ($0.56). HC Wainwright currently has a “Buy” rating on the stock. The consensus estimate for Pharvaris’ current full-year earnings is ($3.12) per share.

A number of other equities analysts have also weighed in on PHVS. Weiss Ratings restated a “sell (d-)” rating on shares of Pharvaris in a research note on Friday, July 17th. Leerink Partners boosted their price objective on Pharvaris from $50.00 to $65.00 and gave the stock an “outperform” rating in a report on Wednesday, September 9th. New Street Research set a $60.00 price objective on shares of Pharvaris in a research report on Friday, August 14th. Wells Fargo & Company raised their target price on shares of Pharvaris from $55.00 to $65.00 and gave the company an “overweight” rating in a research note on Wednesday, September 9th. Finally, Cantor Fitzgerald reiterated an “overweight” rating and set a $65.00 target price on shares of Pharvaris in a research report on Monday, September 14th. Thirteen investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $58.60.

Pharvaris Stock Performance

Shares of PHVS stock opened at $31.68 on Thursday. The company has a market capitalization of $2.07 billion, a PE ratio of -10.39 and a beta of -2.46. Pharvaris has a 52-week low of $20.65 and a 52-week high of $43.25. The business’s fifty day moving average is $34.91 and its 200 day moving average is $32.29.

Pharvaris (NASDAQ:PHVS) last posted its earnings results on Wednesday, August 12th. The company reported ($0.81) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.75) by ($0.06).

Insider Buying and Selling at Pharvaris

In other news, President Peng Lu sold 100,000 shares of the company’s stock in a transaction on Thursday, September 17th. The shares were sold at an average price of $35.00, for a total value of $3,500,000.00. Following the completion of the sale, the president owned 64,953 shares of the company’s stock, valued at approximately $2,273,355. This represents a 60.62% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Johannes Gerardus Chri Schikan sold 200,000 shares of the stock in a transaction on Thursday, September 17th. The shares were sold at an average price of $35.00, for a total transaction of $7,000,000.00. Following the transaction, the director directly owned 115,167 shares in the company, valued at approximately $4,030,845. This represents a 63.46% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders sold 513,102 shares of company stock valued at $18,643,666. 11.84% of the stock is currently owned by corporate insiders.

Institutional Trading of Pharvaris

Several hedge funds have recently added to or reduced their stakes in PHVS. Quantbot Technologies LP bought a new position in shares of Pharvaris during the second quarter valued at about $41,000. CoreCap Advisors LLC purchased a new stake in Pharvaris during the 2nd quarter valued at about $93,000. Public Employees Retirement System of Ohio purchased a new stake in Pharvaris during the 2nd quarter valued at about $196,000. Algert Global LLC bought a new position in Pharvaris during the 2nd quarter worth approximately $238,000. Finally, Persistent Asset Partners Ltd bought a new position in Pharvaris during the 2nd quarter worth approximately $273,000.

About Pharvaris

Pharvaris N.V. (NASDAQ:PHVS) is a biopharmaceutical company focused on developing oral therapies for hereditary angioedema (HAE) and other diseases associated with bradykinin-mediated swelling. HAE is a rare genetic disorder that can cause recurring, potentially life-threatening attacks affecting areas such as the skin, gastrointestinal tract and airways.

The company’s lead program is deucrictibant, an orally administered small-molecule bradykinin B2 receptor antagonist formerly known as PHA121.